Biontech and genmab expand global strategic collaboration to develop and commercialize novel immunotherapy candidates

Mainz, germany, and copenhagen, denmark, august 5, 2022 – biontech se (nasdaq: bntx, “biontech”) and genmab a/s (“genmab”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. under this expansion, biontech and genmab will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications. since 2015, the companies have been working on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options for cancer patients.
BNTX Ratings Summary
BNTX Quant Ranking